Chronic myelomonocytic leukemia with double activating KRAS mutations: molecular characterization of an uncommon case
Murillo Ramos, E.; Afanador Ayala, C. H.; Palacio Rua, K. A.; Rodriguez Cardenas, A.; Ramirez Gaviria, G. C.; Cristancho Salgado, C. M.; Durango Calle, N. E.; Cano Granda, D.; Hinestroza Cordoba, A.; Herrera Patino, J.; Muneton Pena, C. M.; Vasquez Palacio, G. d. J.; Garcia Gomez, J. F.; Santiago Pacheco, V.; Sandoval Mesa, J.
Show abstract
Chronic myelomonocytic leukemia (CMML) is a clonal myelodysplastic/myeloproliferative neoplasm characterized by persistent monocytosis and heterogeneous risk of progression to acute leukemia. Mutations within the RAS/MAPK signaling pathway, particularly involving KRAS, are linked to a proliferative disease phenotype and adverse prognosis. We report the first Colombian CMML case harboring two concurrent activating KRAS mutations (p.G12S and p.G13D). Both variants were detected at variant allele frequencies of 17% and 21% in a female patient in her late 50s presenting with marked leukocytosis, anemia, and thrombocytopenia. The coexistence of these mutations suggests synergistic hyperactivation of the RAS/MAPK pathway, likely driving clinical aggressiveness and therapeutic resistance. This case delineates a rare molecular subgroup within CMML and highlights the critical role of comprehensive genomic profiling to improve prognostic accuracy and inform precision medicine approaches.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- ARPP19 promotes MYC expression and associates with patient relapse in acute myeloid leukemia 93%
- Mutational Profile Enables The Identification Of A High Risk Subgroup In Myelodysplastic Syndromes With Isolated Trisomy 8 93%
- Tyrosine kinase inhibitor independent gene expression signature in CML offers new targets for LSPC eradication therapy 93%
Similar papers in this journal
- Clinical Impact of Panel Based Error Corrected Next Generation Sequencing versus Flow Cytometry to Detect Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) 92%
- Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core 91%
- DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes 91%
Similar papers in this journal
- CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma 92%
- High WEE1 expression is independently linked to poor survival in multiple myeloma 92%
- Real World Predictors of Response and 24-month survival in high-grade TP53 -mutated Myeloid Neoplasms 92%
Similar papers in this journal
- Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms 93%
- Inhibition of Casein Kinase 2 induces cell death in chronic myelogenous leukemia cells resistant to tyrosine kinase inhibitors 93%
- Prediction of myeloid malignant cells in Fanconi anemia using machine learning 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.